Objective Multidrug-resistance (MDR) is considered to be the major obstacle for cancer chemotherapy.In order to study tumor MDR in vitro, we designed this study to establish human multidrug-resistant Bladder cancer pumc-91/ADM cell line and investigate its biological characteristics. Methods MDR cell line (Pumc-91/ADM) was induced by wise selection on exposure to increasing dose of Adriamycin (ADM).Cell growth was measured and multidrug resistance to multi-anticancer agents was evaluated by MTT Assay.Flow cytometry was performed to determine cell cycle and the ADM concentration of cell line. The expression of MDR-related genes were determined with reverse polymerase chain reaction (RT-PCR). Results Compared to Pumc-91, the Pumc-91/ADM cell had a prolonged doubling time. The number of cells in S-phase was decreased in Pumc-91/ADM while those in G1 and G2 phase increased. The Pumc-91/ADM cell was 10 times more resistant to ADM than the Pumc-91 parent. The Pumc-91/ADM cell exhibited cross-resistance to methotrexate, vincristine, cisplatin, epirubicin. RT-PCR showed that mRNA expression of GST was significantly increased in Pumc-91/ADM. Conclusion Pumc-91/ADM is human multidrug-resistant, and it offers a model with MDR phenotype for the study of MDR in human bladder cancer.

Animals ; Humans ; MicroRNAs ; genetics ; Neoplasms ; genetics ; pathology ; RNA Interference ; RNA, Neoplasm ; genetics ; RNA, Small Interfering ; genetics

Objective This study examined the effects of Midazolum-ketamine oral solution (MKOS) on the expression of N-methyl-D-aspartate receptor 1 (NMDAR1) and gamma-aminobutyric acid (GABA)A receptors (GABAAR) mRNA in the cerebral cortex of rat, in order to investigate the sedation mechanism of MKOS. Methods Fifty Sprague-Dawley(SD) rats were divided into ten groups according to the observed time after MKOS administration (0,5,10, 15,30,60,90,120,240 and 360 minutes, n =5 each). The 0 minute group(control group) received 0.9% saline instead. Immunohistochemical staining and in situ hybridization were used to detect the expressions of NMDAR1 and GABAAR mRNA in the cerebral cortex. Results Both GABAAR and NMDAR1 all expressed in the glial cells of cerebral cortex. The expression of NMDAR1 in control group was strong. The expression of NMDAR1 became weaker during 15 to 90 minutes after administration of MKOS (P＜0.05). The expression of GABAAR mRNA in control group was weaker,while became stronger during 30 to 90 minutes after administration of MKOS (P ＜0. 05). Conclusion MKOS may play sedation by strengthening the expression of GABAAR and suppressing the expression of NMDAR1 in the cerebral cortex.

Objective Intramuscular ketamine is often used for premedication in children. Premeditation can also be administered perorally in children. The aim of this study was to evaluate the efficacy of different compounds of ketamine given perorally as premedication in children. Methods Seventy-five ASA Ⅰ- Ⅱ pediatnc patients weighing 10-30 kg undergoing urologic operation were randomly divided into 5 groups of 15 patients each : (1) control group received atropme 0.015 mg ? kg-1 im 30 min before surgery; (2) DA group received intramuscular diazepam 0.2 mg?kg-1 and atropine 0.015 mg?kg-1 30 min before operation; (3) (4) (5) KMA groups received ketamine 3 mg?kg-1 (K3MA) or5mg?kg-1 (K5MA) or 8mg?kg-1 ( K8 MA) + midazolam 0.5 mg?kg-1 + atropine 0.03 mg?kg per os 30 min before operation. SpO2 and heart rate (HR) were monitored and recorded before premedication and at 0, 5, 10, 15, 20, 30 and 40 min after premedication. Peak effect time, duration of operation and emergence time were also recorded. Sedation, anxiolysis and behaviour at separation from parents, during venepuncture and induction were graded and assessed. Results There was no significant difference in duration of operation among the five groups. The peak effect time in the three KMA groups was shorter than that in control and DA group and was shortest in K8MA group. The three KMA groups were significantly better than control and DA group and the K8 MA group was the best in terms of sedation, anxiolysis and analgesia. The incidence of adverse effects like diploplia headache and agitation was higher in K8MA group. Conclusion K5MA group provides satisfactory sedation and analgesia similer to Kg MA group with less side-effects, so is the oral ketamine compound of choice for premedication in children.

Objective To understand the effects of NO signal system on the ciliary beating frequency (CBF) of airway epithelial cellMethods Nine normal male Sprague-Dawley rats were anesthetized with isoflurane Their tracheas were rapidly removed using aseptic technique The mucosa of trachea were cut into 1mm2 explants and cultured in DMEM The explants were divided into 5 groups as bellow: L-Arg group, 1-Hydroxy-2-oxo-3-(N-ethyl-2-aminoethyl)-3-ethyl-1-triazene (NOC-12) group, D-Arg group, 8-Br-cGMP group, and phosphate buffered saline (PBS)group Actively beating ciliated cells were observed, and their motion was quantified by measuring CBF using phase-contrast microscopy and videotape analysis Results L-Arg increased CBF from (7 43?0 75)Hz to(8 59?0 93)Hz (P

Objective To understand the modulating mechanisms in ciliary motility by NO signal pathway. Methods L arginine, the preferred substrate of NOS, was employed to act upon the cultured rat ciliated epithelia. After pre incubating with L NMMA, a NOS inhibitor, or ODQ,a sGC inhibitor, or Rp 8 Br cGMPS, an antagonist of PKG respectively, tissues were contacted with L arginine again. Ciliary beating frequency (CBF) was measured by phase contrast microscope and videotape analysis. Results L arginine increased CBF siginficantly. The effect of L arginine on CBF was blocked by L NMMA, ODQ or Rp 8 Br cGMPS.Conclusion L arginine may increase CBF via NO sGC cGMP PKG pathway.

Objective: To evaluate the effect and safety of neoadjuvant chemotherapy combined with PA-MSHA injection for breast cancer patients. Methods: An open randomized controlled clinical trial was con-ducted. Fourty patients with breast cancer were randomly assigned to neoadjuvant chemotherapy group (the control group, n=20) and neoadjuvant chemotherapy combined with PA-MSHA injection group (the experi-ment group, n=20). The evaluation of therapeutic effect was carried out when the treatment was completed. Kamofsky score was recorded before and after therapy. Venous blood was drawn before and after therapy and immune function (IFN-γ, IL-2, IL-4, and IL-10) and other indicators (Caspase-3, VEGF, MMP-2 and MMP-9) were measured by double antibody ELISA test. Adverse effects of PA-MSHA during therapy were ob-served and recorded. Results: The overall response rate (RR) in the experiment group was significantly higher than that in the control group (P<0.05). No significant difference was found in the pathologic complete remis-sion (pCR) between the experiment group and the control group (P>0.05). In the experimental group, pCR was significantly different before and after therapy (P<0.01). The score in the experimental group was signifi-cantly higher than that in the control group after therapy (P<0.01). With the treatment of chemotherapy and PA-MSHA injection, IFN-γ and IL-2 levels were significantly higher while IL-4 and IL-10 levels were significant-ly lower in the experiment group (P<0.05). A significant increase in serum Caspase-3 and a significant de-crease in serum VEGF, MMP-2 and MMP-9 (P<0.05) after therapy were also observed in the experimental group. The level of serum MMP-9 was decreased significantly (P=<0.05) after therapy in the control group. Con-clusion: Neoadjuvant chemotherapy combined with PA-MSHA injection can significantly improve the RR of breast cancer patients, enhance their cellular immune function, induce the apoptosis and restrain the metasta-sis of breast cancer cells. The PA-MSHA has been proved to be an ideal supplementary therapy for breast cancer.

Objective To explore an optimal treatment and to study the prognosis related factors of breast cancer patients with local recurrence after mastectomy. Methods From 2002. 7 to 2005. 2, 477female patients with loco-regional recurrence of breast cancer treated in Tianjin Cancer Hospital were analyzed retrospectively. Results In 477 cases, recurrence within 1 year after mastectomy accounted for 26. 2% , recurrence within 2 years accounted for 61. 2%. There were 310 cases with metastasis after local recurrence was diagnosed, accounting for 65.0%. 5-year total survival rate after recurrence is 48.4%.Local control rates varied in subgroups with different recurrence site, clinical subtypes, radiotherapy fields,with or without radiotherapy, surgical resection or excisional biopsy ( P<0. 05 ). There was a statistical difference in distant metastasis rate and 5-year survival rate among subgroups which had different clinical stage of primary tumor, disease-free interval, clinical subtypes or treatment methods ( P<0. 05 ). Simplistic treatment option, late clinical stage of primary tumor and triple-negative breast cancer were the independent factors predicting poor prognosis for recurrent breast cancer ( P<0.05 ). Conclusions Multi-site recurrence and triple-negative breast cancer lead to a poor local control. Local expansion of radiotherapy combined with surgery improves the local control rate. Patients with late clinical stage of primary tumor,recurrence within 2 years, triple-negative breast cancer are likely to have distant metastasis when recurrence is diagnosed. Combined treatment program improves survival rate.

Antiviral Agents ; Hepatitis B, Chronic ; Hepatitis C, Chronic ; Humans

Aneurysm, Dissecting ; etiology ; Aortic Aneurysm ; complications ; Aortic Rupture ; Humans ; Male ; Middle Aged ; Sinus of Valsalva ; Ventricular Septum